Details of the Drug Combinations

General Information of This Drug (ID: DMYURI6)

• Drug Name: Raltegravir (DMYURI6)
• Synonyms: RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL

Indication

Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

54 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acetazolamide + Raltegravir	DCCU0B9	Acetazolamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aprepitant + Raltegravir	DC0GG2V	Aprepitant	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Arfolitixorin + Raltegravir	DCYXKHL	Arfolitixorin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Armodafinil + Raltegravir	DC2DPIR	Armodafinil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Auranofin + Raltegravir	DCTEL6A	Auranofin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Bepridil + Raltegravir	DCVO4QR	Bepridil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Carglumic acid + Raltegravir	DCZTQOE	Carglumic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Cerivastatin + Raltegravir	DCAAS2P	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Chlorzoxazone + Raltegravir	DC3DW5K	Chlorzoxazone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Clascoterone + Raltegravir	DCFX7ZP	Clascoterone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Crotamiton + Raltegravir	DCMSMVV	Crotamiton	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Dactinomycin + Raltegravir	DCLO3VT	Dactinomycin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Diazoxide + Raltegravir	DCAYJRX	Diazoxide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Dihydroergotamine + Raltegravir	DCJO4I8	Dihydroergotamine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Docetaxel + Raltegravir	DCV9D2P	Docetaxel	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
ETHISTERONE + Raltegravir	DC3YWDQ	ETHISTERONE	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Flavonoid derivative 1 + Raltegravir	DCXRV7G	Flavonoid derivative 1	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
FORMESTANE + Raltegravir	DCJ8GK4	FORMESTANE	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Gefitinib + Raltegravir	DC757EH	Gefitinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Idarubicin + Raltegravir	DC6Q1TC	Idarubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Imatinib + Raltegravir	DCLKJAH	Imatinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Lacosamide + Raltegravir	DCZD34V	Lacosamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Linagliptin + Raltegravir	DCJNOPM	Linagliptin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Mebendazole + Raltegravir	DCSL45X	Mebendazole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Meclofenamic acid + Raltegravir	DCPBZZX	Meclofenamic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Mefloquine + Raltegravir	DC4KDHN	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Methotrexate + Raltegravir	DCDU2T1	Methotrexate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Mycophenolic acid + Raltegravir	DCK98K5	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Niclosamide + Raltegravir	DC7FJDW	Niclosamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Pazopanib HCl + Raltegravir	DC24OPM	Pazopanib HCl	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Pinacidil + Raltegravir	DCU1G8A	Pinacidil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
PMID28460551-Compound-2 + Raltegravir	DCU9VUA	PMID28460551-Compound-2	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Pyrazinamide + Raltegravir	DCEYC9T	Pyrazinamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Dantrolene	DCVS3N7	Dantrolene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Fomepizole	DCHQS1U	Fomepizole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Triapine	DCJ7844	Triapine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + IT-141	DCG3RGD	IT-141	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + LY03004	DCU43WK	LY03004	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Fenoprofen	DC2Q5WD	Fenoprofen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Allopurinol	DCBC3A7	Allopurinol	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Idarubicin	DC1N5VV	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
Raltegravir + Abacavir	DCUNDG5	Abacavir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Methylene blue	DCZU8SN	Methylene blue	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Artemisinin	DCQ4RDS	Artemisinin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Leflunomide	DCVZM4I	Leflunomide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Chlorambucil	DCESKH1	Chlorambucil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Doxorubicin	DCK7680	Doxorubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Acetohydroxamic Acid	DCJO25J	Acetohydroxamic Acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Azatadine	DCKLQVU	Azatadine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Tetracycline	DCIKBTO	Tetracycline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Raltegravir + Cytarabine	DCHT9OH	Cytarabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Trimethobenzamide + Raltegravir	DC25S5H	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Vinblastine + Raltegravir	DCGBFKP	Vinblastine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Zileuton + Raltegravir	DCXBBV7	Zileuton	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Abacavir + Raltegravir	DCVCU7P	Abacavir	HIV	[4]
Amlodipine + Raltegravir	DC5GQF8	Amlodipine	HIV	[5]
Atazanavir + Raltegravir	DCK60JV	Atazanavir	HIV	[6]
Boceprevir + Raltegravir	DCUAY9A	Boceprevir	HIV Infections	[7]
Citalopram + Raltegravir	DC6PTSC	Citalopram	HIV	[8]
Darunavir + Raltegravir	DC6DLN4	Darunavir	HIV-1 Infection	[9]
Famotidine + Raltegravir	DCGL2JR	Famotidine	HIV-1 Infection	[10]
Lamotrigine + Raltegravir	DC47DV7	Lamotrigine	HIV Infection	[11]
Lopinavir + Raltegravir	DC3HPZB	Lopinavir	Human Immunodeficiency Virus Infection	[12]
Omeprazole + Raltegravir	DCYDJKZ	Omeprazole	HIV-1 Infection	[10]
Tenofovir + Raltegravir	DC85GHN	Tenofovir	HIV Infections	[13]
Tenofovir + Raltegravir	DCEHPPH	Tenofovir	HIV	[14]
Emtricitabine + Raltegravir	DCRSKBT	Emtricitabine	Primary Biliary Cholangitis	[15]
Lamivudine + Raltegravir	DCL834N	Lamivudine	HIV Infections	[16]
Atorvastatin + Raltegravir	DCNKSDC	Atorvastatin	Aging-related Inflammation in HIV-infected Patients	[17]
Lamivudine + Raltegravir	DCJC0HZ	Lamivudine	Hiv	[18]

References

• [1] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [4] ClinicalTrials.gov (NCT00765271) Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects
• [5] ClinicalTrials.gov (NCT01841593) A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
• [6] ClinicalTrials.gov (NCT00768989) Phase IIB Pilot of Atazanavir + Raltegravir
• [7] ClinicalTrials.gov (NCT01288417) Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
• [8] ClinicalTrials.gov (NCT01978782) Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).
• [9] ClinicalTrials.gov (NCT01641367) A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
• [10] ClinicalTrials.gov (NCT01000818) A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
• [11] ClinicalTrials.gov (NCT00618241) Pharmacokinetic Study on Raltegravir and Lamotrigine
• [12] ClinicalTrials.gov (NCT00711009) Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
• [13] ClinicalTrials.gov (NCT00977756) IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
• [14] ClinicalTrials.gov (NCT01214759) Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
• [15] ClinicalTrials.gov (NCT03954327) Combination Antiretroviral Therapy (cART) for PBC
• [16] ClinicalTrials.gov (NCT03311945) Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
• [17] ClinicalTrials.gov (NCT02577042) Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
• [18] ClinicalTrials.gov (NCT03205566) Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection